# US 2016/0250243 A1 · Use of icaritin in preparing medicament for preventing or treating hematocytopenia

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0250243 A1
- Document ID: US20160250243A1
- Status: Published application
- Kind: A1
- Application number: 15/030,671
- Filed: 2014-10-20
- Published: 2016-09-01
- Earliest claimed: 2013-10-21
- Assignees: Lunan Pharmaceutical Group Corporation
- Applicants: Lunan Pharmaceutical Group Corporation
- Inventors: Zhiquan ZHAO; Jingchun YAO; Xin LI; Yongxia GUAN; Guangyan LI
- Web page: https://patentgrep.com/patent/US20160250243A1

## CPC

- A61K 31/7048: having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin {, digitoxin or digoxin}
- A61P 7/00: Drugs for disorders of the blood or the extracellular fluid
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/1075: {Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers (A61K9/0026 takes precedence)}
- A61K 9/16: Agglomerates; Granulates; Microbeadlets {; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction (A61K9/20 takes precedence if the final form is a tablet; microspheres with drug-free outer coating, microcapsules A61K9/50; mixture of different granules, microcapsules, (coated) microparticles A61K9/5084; nanoparticles A61K9/51)}
- A61K 9/20: Pills, tablets, {discs, rods (A61K9/0004, A61K9/0007, A61K9/0056, A61K9/0065 take precedence; for reconstitution of a drink A61K9/0095)}
- A61K 9/48: Preparations in capsules, e.g. of gelatin, of chocolate {(A61K9/0004 takes precedence; bite capsules A61K9/0056)}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 7/04: Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A61P 7/06: Antianaemics
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present application relates to use of icaritin in preparing a medicament for preventing or treating hematocytopenia. Particularly, icaritin may be used to prevent or treat bone marrow suppression caused by chemotherapeutic drugs, and may also be used to prevent or treat thrombocytopenia, for example, immune thrombocytopenia.

## Claims

### Claim at position 1

1-17. (canceled)

### Claim 18

A method for preventing or treating hematocytopenia comprising administering an effective amount of icaritin to a human in need thereof.

### Claim 19 (depends on 18)

The method according to claim 18, wherein the hematocytopenia is a reduction of the white blood cells or platelets in peripheral blood.

### Claim 20 (depends on 18)

The method according to claim 18, wherein the hematocytopenia is bone marrow suppression induced by radiation or a chemical, or primary myelodysplasia.

### Claim 21 (depends on 20)

The method according to claim 20, wherein the chemical is a chemotherapeutic drug for treating cancer.

### Claim 22 (depends on 21)

The method according to claim 21, wherein the chemotherapeutic drug for treating cancer is docetaxel or tegafur.

### Claim 23 (depends on 18)

The method according to claim 18, wherein the hematocytopenia is thrombocytopenia.

### Claim 24 (depends on 23)

The method according to claim 23, wherein the thrombocytopenia is immune thrombocytopenia or secondary thrombocytopenia.

### Claim 25 (depends on 24)

The method according to claim 24, wherein the immune thrombocytopenia is chronic idiopathic thrombocytopenic purpura.

### Claim 26 (depends on 24)

The method according to claim 24, wherein the secondary thrombocytopenia is induced by bone marrow suppression due to a radiation or a chemical drug.

### Claim 27 (depends on 26)

The method according to claim 26, wherein the chemical drug is docetaxel, cyclophosphamide, or tegafur.

### Claim 28 (depends on 18)

The method according to claim 18, wherein icaritin is administered in the form of an oral formulation or a formulation for parenteral administration, such as an injection.

### Claim 29 (depends on 28)

The method according to claim 28, wherein the oral formulation is a tablet, granule or capsule.

### Claim 30 (depends on 28)

The method according to claim 28, wherein the oral formulation or the injection contains icaritin in an amount of 0.1 to 500 mg per unit dose.

### Claim 31 (depends on 18)

The method according to claim 18, wherein when icaritin is orally administered to human, the dosage is 0.1 mg/kg/d-100 mg/kg/d.

### Claim 32 (depends on 18)

The method according to claim 18, wherein when icaritin is administered to human by injection, the dosage is 0.01 mg/kg-10 mg/kg.

### Claim 33 (depends on 18)

The method according to claim 18, wherein icaritin is administered in the form of solid, liquid, oil, emulsion, gel, aerosol, inhalant, spray, capsule, pill, patch, or suppository.

### Claim 34 (depends on 18)

The method according to claim 18, wherein icaritin is administered in combination with one or more other drugs for treating leukocytopenia or one or more other drugs which are able to increase the amount of platelets, wherein the drugs for treating leukocytopenia are selected from vitamin B4, leucogen, batyl alcohol, and coenzyme A, and the drugs which are able to increase the amount of platelets are selected from interleukin-II, and glucocorticoids such as prednisone.
